These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 26279197)
21. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. Raj R; Frost AE J Heart Lung Transplant; 2005 Jun; 24(6):671-9. PubMed ID: 15949726 [TBL] [Abstract][Full Text] [Related]
22. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720 [TBL] [Abstract][Full Text] [Related]
23. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry. Zaffiri L; Long A; Neely ML; Cherikh WS; Chambers DC; Snyder LD J Heart Lung Transplant; 2020 Oct; 39(10):1089-1099. PubMed ID: 32654913 [TBL] [Abstract][Full Text] [Related]
25. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality. Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929 [TBL] [Abstract][Full Text] [Related]
26. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study. OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912 [TBL] [Abstract][Full Text] [Related]
28. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
29. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742 [TBL] [Abstract][Full Text] [Related]
30. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251 [TBL] [Abstract][Full Text] [Related]
31. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821 [TBL] [Abstract][Full Text] [Related]
32. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586 [TBL] [Abstract][Full Text] [Related]
33. Thoracic presentations of posttransplant lymphoproliferative disorders. Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707 [TBL] [Abstract][Full Text] [Related]
34. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147 [TBL] [Abstract][Full Text] [Related]
35. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340 [TBL] [Abstract][Full Text] [Related]
36. Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation. Kim IC; Kim SH; Youn JC; Kim D; Lee S; Kim H; Kim JJ; Jung MH; Rossano JW; Cherikh WS; Kobashigawa JA; Stehlik J JACC Heart Fail; 2024 Feb; 12(2):395-405. PubMed ID: 38326002 [TBL] [Abstract][Full Text] [Related]
37. Increased risk of PTLD in lung transplant recipients with cystic fibrosis. Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611 [TBL] [Abstract][Full Text] [Related]
38. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. Paranjothi S; Yusen RD; Kraus MD; Lynch JP; Patterson GA; Trulock EP J Heart Lung Transplant; 2001 Oct; 20(10):1054-63. PubMed ID: 11595560 [TBL] [Abstract][Full Text] [Related]
39. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry. Wever-Pinzon O; Edwards LB; Taylor DO; Kfoury AG; Drakos SG; Selzman CH; Fang JC; Lund LH; Stehlik J J Heart Lung Transplant; 2017 Apr; 36(4):407-417. PubMed ID: 27686602 [TBL] [Abstract][Full Text] [Related]
40. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]